Sanofi sees early signs that its Synthorx acquisition could pay off with IL-2 data

Sanofi took another step in its oncology pipeline rebuild with the first clinical evidence that a cornerstone program of its oncology pipeline — precision engineered IL-2 therapy THOR-717 -- may be effective. 

The company presented the first clinical data from the THOR-717 (SAR444245) program Saturday showing that the non-alpha IL-2 led to partial responses in three solid tumor patients in the open-label Phase I/II HAMMER study. The data were presented at the American Association for Cancer Research (AACR) annual meeting...